Chemed Corporation


SKU: CHE-1 Category:


Chemed Corporation: A Tale Of Workforce & Patient Expansion To Catalyze Growth! 


Chemed Corporation’s management recently their financial results for the first quarter of 2024, which ended on March 31, 2024. The earnings showed mixed results, with strong performance from VITAS and weaker metrics from Roto-Rooter. VITAS, Chemed’s healthcare subsidiary, showcased a robust operating performance with an increase in admissions of 4.5% over the previous year. This rise drove a higher patient census, resulting in a 1,835 average daily census (ADC), reflecting an increase of 10.3% when compared to the prior year period. This escalation exceeds the Corporation’s internal projections for the quarter. The rise came from a continued strengthening in the hiring and retaining of licensed staff, with an additional 173 professionals added in the quarter. Chemed’s executives also expressed optimism about the acquisition of Covenant Health and Community Services, expecting operational and financial benefits in 2024 and beyond.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!